title: [Analysis of direct costs of controlling arterial hypertension].
abstract: OBJECTIVE
  To analyse the number of attendances and the direct cost of pharmaceutical prescription arising from a year-long monitoring of hypertense patients.
  
  
  METHODS
  Health Centre.
  
  
  METHODS
  A prospective observation study.
  
  
  METHODS
  220 hypertense patients, undergoing arterial pressure (AP) monitoring, were chosen by means of systematic random sampling.
  
  
  RESULTS
  The variables of age, gender, cardiovascular risk factors, AP, monitoring level (criterion AP < 160-90 mmHg), attendances and treatment used were analysed. The pharmaceutical cost was calculated in line with the dosages and according to the 1990 Vademecum. The monitoring level was 43.6%. The total number of attendances per patient were 12.8 +/- 6.43 and those for hypertension, 7.9 +/- 3.5. Diabetics attended more for hypertension (8.8 vs 7.5, p < 0.05). Pharmaceutical treatment was prescribed for 183 people (83.2%). The number of drugs was correlated with the severity of the hypertension and the number of attendances. Overall drug cost was 429,571 pesetas per month. Average monthly cost per patient was 2,348.69 +/- 2,318.92 pesetas (range 90.5-12,856.5). Angiotensin enzyme conversion inhibitors (AECI) made for the greatest monthly mean cost per patient (4,352.9 pesetas) and diuretics, the least (322.2 pesetas).
  
  
  CONCLUSIONS
  Frequency of attendance is related to the presence of diabetes and the number of drugs prescribed. The introduction of AECI and Calcium antagonists into first-line treatment represents an important increase in the cost of controlling Hypertension.
authors.affiliation: Area Básica de Salud La Mina, Sant Adrià de Besòs, Barcelona.
authors.forename: M
authors.initials: M
authors.lastname: Borrell
authors.forename: M A
authors.initials: MA
authors.lastname: Méndez
authors.forename: T
authors.initials: T
authors.lastname: Gros
authors.forename: M
authors.initials: M
authors.lastname: de la Figuera
authors.forename: J
authors.initials: J
authors.lastname: Davins
authors.forename: M
authors.initials: M
authors.lastname: del Amo
authors.forename: A
authors.initials: A
authors.lastname: Casas
authors.forename: C
authors.initials: C
authors.lastname: Espel
authors.forename: R
authors.initials: R
authors.lastname: Ciurana
mesh_terms: D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics; D000959:Antihypertensive Agents / Q000191:economics; D003365:Costs and Cost Analysis; D048909:Diabetes Complications; D004232:Diuretics / Q000191:economics; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000191:economics* / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009819:Office Visits / Q000191:economics; D011446:Prospective Studies
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004232:Diuretics
vernacular_title: Análisis de los costes directos del control de la hipertensión arterial.